Post-essential Thrombocythemia Myelofibrosis clinical trials at UCSD

1 research study open to eligible people

Showing trials for

  • Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

    open to eligible people ages 18 years and up

    A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

    La Jolla, California and other locations

Our lead scientists for Post-essential Thrombocythemia Myelofibrosis research studies include .

Last updated: